FI51936C - Menetelmä terapeuttisesti käytettävien 3,4-dihydronaftalenonioksi-2-hy droksipropyyliamiinien ja näiden happo-additiosuolojen valmistamiseksi . - Google Patents

Menetelmä terapeuttisesti käytettävien 3,4-dihydronaftalenonioksi-2-hy droksipropyyliamiinien ja näiden happo-additiosuolojen valmistamiseksi .

Info

Publication number
FI51936C
FI51936C FI692717A FI271769A FI51936C FI 51936 C FI51936 C FI 51936C FI 692717 A FI692717 A FI 692717A FI 271769 A FI271769 A FI 271769A FI 51936 C FI51936 C FI 51936C
Authority
FI
Finland
Prior art keywords
dihydronaphthalenoxyoxy
hydroxypropylamines
preparation
acid addition
addition salts
Prior art date
Application number
FI692717A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI51936B (fr
Inventor
Jr John Shavel
Sheldon Farber
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to FI762870A priority Critical patent/FI762870A/fi
Application granted granted Critical
Publication of FI51936B publication Critical patent/FI51936B/fi
Publication of FI51936C publication Critical patent/FI51936C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/38Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C07D303/26Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds having one or more free hydroxyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
FI692717A 1968-09-23 1969-09-23 Menetelmä terapeuttisesti käytettävien 3,4-dihydronaftalenonioksi-2-hy droksipropyyliamiinien ja näiden happo-additiosuolojen valmistamiseksi . FI51936C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI762870A FI762870A (fr) 1968-09-23 1976-10-08

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76185768A 1968-09-23 1968-09-23

Publications (2)

Publication Number Publication Date
FI51936B FI51936B (fr) 1977-01-31
FI51936C true FI51936C (fi) 1977-05-10

Family

ID=25063434

Family Applications (1)

Application Number Title Priority Date Filing Date
FI692717A FI51936C (fi) 1968-09-23 1969-09-23 Menetelmä terapeuttisesti käytettävien 3,4-dihydronaftalenonioksi-2-hy droksipropyyliamiinien ja näiden happo-additiosuolojen valmistamiseksi .

Country Status (15)

Country Link
US (1) US3641152A (fr)
JP (1) JPS4843734B1 (fr)
BE (1) BE739195A (fr)
CH (1) CH525183A (fr)
DE (2) DE1967162C3 (fr)
DK (2) DK125588B (fr)
ES (1) ES371737A1 (fr)
FI (1) FI51936C (fr)
FR (1) FR2018626B1 (fr)
GB (1) GB1223527A (fr)
IT (1) IT1033032B (fr)
NL (1) NL139166B (fr)
NO (1) NO128869B (fr)
SE (1) SE362414B (fr)
ZA (1) ZA695648B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE755071A (fr) * 1969-09-17 1971-02-22 Warner Lambert Pharmaceutical Procede de resolution de la dl-5-/3-(terbutylamino)-2- hydroxy-propoxy/-3,4-dihydro-1(2h) naphtalenone
US3959486A (en) * 1970-05-27 1976-05-25 Imperial Chemical Industries Limited Method for producing β-adrenergic blockage with alkanolamine derivatives
DE2130393C3 (de) * 1970-06-22 1981-02-26 E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) 6,7-Dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanole und ihre Salze mit Säuren sowie ihre Verwendung bei der Bekämpfung von Herzerkrankungen
FR2119843B1 (fr) * 1970-12-28 1974-03-22 Laroche Navarro Labo
JPS5122737Y2 (fr) * 1972-12-30 1976-06-11
US3966749A (en) * 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
GB1493848A (en) * 1975-07-24 1977-11-30 Beecham Group Ltd Aryltetralins
CH621330A5 (fr) * 1976-05-14 1981-01-30 Sandoz Ag
DE2810869A1 (de) * 1977-03-24 1978-09-28 Sandoz Ag 3-amino-2-hydroxypropoxy-derivate, ihre herstellung und verwendung
US4176183A (en) * 1977-05-02 1979-11-27 Merck & Co., Inc. Novel naphthyridines
US4270005A (en) * 1977-11-14 1981-05-26 Pfizer Inc. 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor
CH641147A5 (de) * 1979-01-17 1984-02-15 Sandoz Ag 3-amino-2-hydroxypropoxyaryl-derivat, seine herstellung und dieses enthaltende heilmittel.
DE2943406A1 (de) * 1979-10-26 1981-05-07 Basf Ag, 6700 Ludwigshafen Aminoderivate des 2-methyl-5-(2-hydroxystyryl)-1,3,4-thiadiazols
FR2507181A1 (fr) * 1981-06-05 1982-12-10 Sanofi Sa Nouveaux ethers de phenol actifs sur le systeme cardiovasculaire, leur procede de preparation et leur utilisation dans des medicaments
SE8801518D0 (sv) * 1988-04-22 1988-04-22 Astra Pharma Prod A novel process
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
ES2065278B1 (es) * 1993-06-24 1995-09-01 Medichem Sa Procedimiento de obtencion enantioselectivo del levobunolol.
ATE330633T1 (de) * 2000-07-27 2006-07-15 Pharmacia Corp Epoxy-steroidaler aldosteronantagonist und beta- adrenergischer antagonist-kombinationstherapie zur behandlung von kongestivem herzversagen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1023214A (en) 1962-12-17 1966-03-23 Ici Ltd Carbocyclic hydroxyamines

Also Published As

Publication number Publication date
DE1948144B2 (de) 1979-05-03
US3641152A (en) 1972-02-08
DK125588B (da) 1973-03-12
ZA695648B (en) 1971-03-31
CH525183A (de) 1972-07-15
JPS4843734B1 (fr) 1973-12-20
NL139166B (nl) 1973-06-15
DE1967162B1 (de) 1980-07-31
FR2018626A1 (fr) 1970-06-26
DE1967162C3 (de) 1981-03-19
IT1033032B (it) 1979-07-10
NO128869B (fr) 1974-01-21
SE362414B (fr) 1973-12-10
GB1223527A (en) 1971-02-24
FI51936B (fr) 1977-01-31
BE739195A (fr) 1970-03-23
ES371737A1 (es) 1972-03-16
DE1948144A1 (de) 1970-03-26
NL6914077A (fr) 1970-03-25
FR2018626B1 (fr) 1973-06-08
DK128536B (da) 1974-05-20
DE1948144C3 (de) 1980-01-17

Similar Documents

Publication Publication Date Title
FI48731C (fi) Menetelmä terapeuttisesti käytettävien, 1-asemassa aminoalkyyliryhmäll ä substituoitujen ftalaanien ja iso-kromaanien ja näiden happoadditios uolojen valmistamiseksi.
FI49300C (fi) Menetelmä terapeuttisesti aktiivisten 1,4-dihydropyridiinijohdannaiste n valmistamiseksi.
FI51190C (fi) Menetelmä terapeuttisesti vaikuttavien, erityisesti koronadilatooriste n N-(3,4,5-trimetoksi-kinnamoyyli)-piperatsiinijohdannaisten valmistam iseksi.
FI51936C (fi) Menetelmä terapeuttisesti käytettävien 3,4-dihydronaftalenonioksi-2-hy droksipropyyliamiinien ja näiden happo-additiosuolojen valmistamiseksi .
FI51350C (fi) Menetelmä virtsaneritystä edistävien 6-sulfamyyli-1,2,3,4-tetrahydro-4 -kinatsolinonien ja niiden suolojen valmistamiseksi.
FI52339C (fi) Menetelmä terapeuttisesti aktiivisten 1,4-dihydropyridiinijohdannaiste n valmistamiseksi.
CH546788A (fr) Procede de preparation d'agents anti-inflammatoires.
FI49977C (fi) Menetelmä terapeuttisesti käytettävien 3-alkoksi-tianafteeni-2-karboks iamidien ja niiden 1,1-dioksidien valmistamiseksi
FI52338C (fi) Menetelmä terapeuttisesti käytettävien 1,2,3,6-tetrahydropyridiinijohd annaisten ja niiden happoadditiosuolojen valmistamiseksi.
FI49720C (fi) Menetelmä terapeuttisesti vaikuttavien 2-metyyli-3-karbonihappoamidoki noksaliini-di-N-oksidien-(1,4) valmistamiseksi.
FI52715C (fi) Menetelmä terapeuttisesti käytettävien vitamiini A-happoamidien valmis tamiseksi.
FI48728C (fi) Analogiamenetelmä terapeuttisesti käytettävien fenyylietikkahappojohda nnaisten valmistamiseksi.
FI49827C (fi) Menetelmä terapeuttisesti vaikuttavien substituoitujen 3-hydroksimetyy li-isokinoliinien valmistamiseksi.
IL36435A (en) Methyl 7-o-methyl-6,8-dideoxy-6-(trans-1-methyl-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-l-threo-alpha-d-galacto-octopyranoside,the acid addition salts thereof and the production of these
FI51176C (fi) Menetelmä terapeuttisesti käytettävien 4-aryyli-1-(4,4-diaryylibutyyli )-4-hydroksipiperidiinien ja näiden happoadditiosuolojen valmistamisek si.
FI51479C (fi) Menetelmä terapeuttisesti käytettävän 3,3-disubstituoidun heksahydro-1 H-atsepiiniyhdisteen valmistamiseksi.
FI49718C (fi) Menetelmä terapeuttisesti vaikuttavien 2-halogeenimetyyli-3-karbonihap poamidokinoksaliini-di-N-oksidien-(1,4) valmistamiseksi.
FI49166C (fi) Menetelmä valmistaa beta-stimuloivaa 6,7-diasyylioksi-tetrahydroisokin oliiniyhdistettä ja sen farmaseuttisesti hyväksyttävää happoadditiosuo laa.
IL31910A0 (en) Indenopyridines,their acid addition salts,and the production thereof
FI51349C (fi) Menetelmä terapeuttisesti vaikuttavien N-substituoitujen 6,7-bentsomor faanien valmistamiseksi.
BR7105511D0 (pt) Processo para a preparacao de derivados 1,4 benzodiazepinicos
FI49417C (fi) Menetelmä farmakologisesti aktiivisten 2,3-dihydro-bentsofuraani-2-kar bonihappojen valmistamiseksi.
FI45450C (fi) Menetelmä terapeuttisesti käyttökelpoisten fentiatsiini-johdannaisten ja niiden suolojen valmistamiseksi
FI45175C (fi) Menetelmä 18-metyyli-19-nor-17alfa-hydroksi-progesteronien ja niiden 1 7alfa-esterien valmistamiseksi.
FI45555C (fi) Menetelmä terapeuttisesti käytettävien strofantidiinityyppisten sydäng lykosidijohdannaisten valmistamiseksi.